Dosing and uses of Zymar, Zymaxid (gatifloxacin ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.3%
- 0.5%
Bacterial Conjunctivitis
Indicated for conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae
Zymar 0.3%
- Days 1-2: Instill 1 gtt to affected eye(s) q2hr while awake, up to 8 xday
- Days 3-7: Instill 1 gtt to affected eye(s) up to QID
Zymaxid 0.5%
- Day 1: Instill 1 gtt to affected eye(s) q2hr while awake, up to 8 xday
- Days 2-7: Instill 1 gtt BID-QID on Days 2-7
Other Indications & Uses
Conjunctivitis, blepharitis, acute meibomianitis, dacryocystitis
Pediatric dosage forms and strengths
ophthalmic solution
- 0.3%
- 0.5%
Bacterial Conjunctivitis
Indicated for conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae
<1 year: Safety and efficacy not established
Zymar 0.3%
- As adults
- Days 1-2: Instill 1 gtt to affected eye(s) q2hr while awake, up to 8 xday
- Days 3-7: Instill 1 gtt to affected eye(s) up to QID
Zymaxid 0.5%
- As adults
- Day 1: Instill 1 gtt to affected eye(s) q2hr while awake, up to 8 xday
- Days 2-7: Instill 1 gtt BID-QID on Days 2-7
Zymar, Zymaxid (gatifloxacin ophthalmic) adverse (side) effects
1-10%
Conjunctival irritation (5-10%)
Incr. lacrimation (5-10%)
Keratitis (5-10%)
Papillary conjunctivitis (5-10%)
Conjunctival hemorrhage (1-4%)
Chemosis (1-4%)
Dry eye (1-4%)
Eye discharge (1-4%)
Eye irritation (1-4%)
Eye pain (1-4%)
Eyelid swelling (1-4%)
Red eye (1-4%)
Visual acuity decr (1-4%)
Taste disturbance (1-4%)
Warnings
Contraindications
Hypersensitivity to quinolones or other components in product
Cautions
Prolonged use may result in overgrowth of nonsusceptible organisms (incl fungi)
Some patients may require slit-lamp biomicroscopy & fluorescein staining
Advice patients not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis
Solution may harm corneal endothelial cells if introduced directly into anterior chamber
Pregnancy and lactation
Pregnancy: There are no available data in pregnant women to inform of a drug-associated risk
Lactation: Excretion in milk unknown; consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Zymar, Zymaxid (gatifloxacin ophthalmic)
Mechanism of action
Fluoroquinolone antibiotic; antibacterial action results from inhibition of DNA gyrase and topoisomerase IV
Pharmacokinetics
Absorption: undetectable systemic
